InsiderTrades.com logo
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
From Stansberry Research   |   Ad
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Click here to find out what to do.
Ronald E. Bruehlman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Ronald Bruehlman Biography and Net Worth

Insider of IQVIA
Ron Bruehlman is Executive Vice President and Chief Financial Officer of IQVIA. He is responsible for the controllers, FP&A, treasury, tax, internal audit, corporate development, and corporate strategy functions. He assumed this position after serving from October 2016 through July 2020 as Senior Advisor to the CEO of IQVIA, playing an active role in the integration of IMS Health and Quintiles. Prior to that, Ron was Chief Financial Officer of IMS Health from July 2011 through September 2016. He joined IMS Health following the 2010 leveraged buyout led by TPG Capital and subsequently guided the company through its 2014 IPO and its merger of equals with Quintiles in October 2016.

Before joining IMS Health, Ron had a 23-year career at United Technologies Corporation (UTC), where he held multiple senior finance leadership roles of increasing responsibility. These included running UTC’s global corporate development and strategy group, serving as Chief Financial Officer of Carrier Corporation, leading the corporate financial planning and analysis function for UTC, running financial analysis and planning for Otis Elevator, and leading UTC’s investor relations function.

Ron currently serves as a board member and Audit Committee Chair for Atotech Ltd., an NYSE-listed global market leader in plating technologies. Ron previously chaired the board of Q2 Solutions, a joint venture between IQVIA and Quest Diagnostics.

What is Ronald E. Bruehlman's net worth?

The estimated net worth of Ronald E. Bruehlman is at least $3.92 million as of August 4th, 2020. Mr. Bruehlman owns 16,751 shares of IQVIA stock worth more than $3,923,922 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Bruehlman may own. Additionally, Mr. Bruehlman receives a salary of $2,140,000.00 as Insider at IQVIA. Learn More about Ronald E. Bruehlman's net worth.

How old is Ronald E. Bruehlman?

Mr. Bruehlman is currently 63 years old. There are 3 older executives and no younger executives at IQVIA. Learn More on Ronald E. Bruehlman's age.

What is Ronald E. Bruehlman's salary?

As the Insider of IQVIA Holdings Inc., Mr. Bruehlman earns $2,140,000.00 per year. The highest earning executive at IQVIA is Mr. Ari Bousbib, CEO & Chairman, who commands a salary of $7,150,000.00 per year. Learn More on Ronald E. Bruehlman's salary.

How do I contact Ronald E. Bruehlman?

The corporate mailing address for Mr. Bruehlman and other IQVIA executives is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. IQVIA can also be reached via phone at (919) 998-2000 and via email at [email protected]. Learn More on Ronald E. Bruehlman's contact information.

Has Ronald E. Bruehlman been buying or selling shares of IQVIA?

Ronald E. Bruehlman has not been actively trading shares of IQVIA within the last three months. Most recently, on Tuesday, August 4th, Ronald E. Bruehlman bought 10,000 shares of IQVIA stock. The stock was acquired at an average cost of $159.94 per share, with a total value of $1,599,400.00. Following the completion of the transaction, the insider now directly owns 16,751 shares of the company's stock, valued at $2,679,154.94. Learn More on Ronald E. Bruehlman's trading history.

Who are IQVIA's active insiders?

IQVIA's insider roster includes Ari Bousbib (Insider), Ronald Bruehlman (Insider), John Connaughton (Director), John Danhakl (Director), Kevin Knightly (Insider), Michael McDonnell (CFO), Ronald Rittenmeyer (Director), and Eric Sherbet (Insider). Learn More on IQVIA's active insiders.

Are insiders buying or selling shares of IQVIA?

In the last year, insiders at the medical research company sold shares 7 times. They sold a total of 87,540 shares worth more than $20,013,870.89. The most recent insider tranaction occured on March, 1st when insider Ari Bousbib sold 31,678 shares worth more than $7,936,289.34. Insiders at IQVIA own 1.6% of the company. Learn More about insider trades at IQVIA.

Information on this page was last updated on 3/1/2024.

Ronald E. Bruehlman Insider Trading History at IQVIA

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/4/2020Buy10,000$159.94$1,599,400.0016,751View SEC Filing Icon  
See Full Table

Ronald E. Bruehlman Buying and Selling Activity at IQVIA

This chart shows Ronald E Bruehlman's buying and selling at IQVIA by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IQVIA Company Overview

IQVIA logo
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $234.08
Low: $232.42
High: $239.89

50 Day Range

MA: $245.50
Low: $227.17
High: $259.15

2 Week Range

Now: $234.08
Low: $167.42
High: $261.73

Volume

1,061,416 shs

Average Volume

973,451 shs

Market Capitalization

$42.49 billion

P/E Ratio

32.11

Dividend Yield

N/A

Beta

1.5
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
From Stansberry Research   |   Ad
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Click here to find out what to do.